Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
After finishing at $31.65 in the prior trading day, Viking Therapeutics Inc (NASDAQ: VKTX) closed at $31.99, up 1.07%. In other words, the price has increased by $1.07 from its previous closing price. On the day, 2.87 million shares were traded. VKTX stock price reached its highest trading level at $32.94 during the session, while it also had its lowest trading level at $31.79.
Ratios:
Our goal is to gain a better understanding of VKTX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 28.34 and its Current Ratio is at 28.34. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Canaccord Genuity on October 29, 2025, initiated with a Buy rating and assigned the stock a target price of $106.
On April 29, 2025, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $104.
On April 08, 2025, Goldman started tracking the stock assigning a Neutral rating and target price of $30.Goldman initiated its Neutral rating on April 08, 2025, with a $30 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 05 ’26 when ZANTE GREG sold 57,661 shares for $32.90 per share. The transaction valued at 1,896,969 led to the insider holds 189,891 shares of the business.
Mancini Marianna sold 57,661 shares of VKTX for $1,901,405 on Jan 05 ’26. The Chief Operating Officer now owns 409,190 shares after completing the transaction at $32.98 per share. On Jan 05 ’26, another insider, Lian Brian, who serves as the President & CEO of the company, sold 233,409 shares for $32.96 each. As a result, the insider received 7,692,121 and left with 2,499,291 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VKTX now has a Market Capitalization of 3616032512 and an Enterprise Value of 2902217728.
Stock Price History:
The Beta on a monthly basis for VKTX is 0.75, which has changed by -0.17721194 over the last 52 weeks, in comparison to a change of 0.19362879 over the same period for the S&P500. Over the past 52 weeks, VKTX has reached a high of $43.15, while it has fallen to a 52-week low of $18.92. The 50-Day Moving Average of the stock is -11.44%, while the 200-Day Moving Average is calculated to be 4.76%.
Shares Statistics:
The stock has traded on average 3.61M shares per day over the past 3-months and 3143590 shares per day over the last 10 days, according to various share statistics. A total of 112.45M shares are outstanding, with a floating share count of 109.70M. Insiders hold about 2.83% of the company’s shares, while institutions hold 65.24% stake in the company. Shares short for VKTX as of 1765756800 were 24029319 with a Short Ratio of 6.66, compared to 1763078400 on 24785654. Therefore, it implies a Short% of Shares Outstanding of 24029319 and a Short% of Float of 25.480000000000004.
Earnings Estimates
Currently, 14.0 analysts are dedicated to thoroughly evaluating and rating the performance of Viking Therapeutics Inc (VKTX) in the stock market.The consensus estimate for the next quarter is -$0.94, with high estimates of -$0.76 and low estimates of -$1.19.
Analysts are recommending an EPS of between -$2.07 and -$2.87 for the fiscal current year, implying an average EPS of -$2.61. EPS for the following year is -$3.72, with 13.0 analysts recommending between -$3.13 and -$4.94.
